Clinical Trial Update: A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems [Phase 1]

View source ↗

Summary

Phase 1 study evaluating how Avenciguat (BI-685509) is absorbed and processed in people with and without liver disease; the trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease

Drugs mentioned

• Avenciguat

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Healthy, Liver Diseases | Phase 1 | Status: TERMINATED